NTLA
Intellia Therapeutics, Inc. NASDAQ Listed May 6, 2016$13.85
After hrs
$13.77
-0.58%
Mkt Cap $1.6B
52w Low $6.83
32.8% of range
52w High $28.25
50d MA $13.65
200d MA $13.18
P/E (TTM)
-3.5x
EV/EBITDA
-2.3x
P/B
2.1x
Debt/Equity
0.1x
ROE
-61.5%
P/FCF
-2.7x
RSI (14)
—
ATR (14)
—
Beta
1.99
50d MA
$13.65
200d MA
$13.18
Avg Volume
4.3M
About
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and al…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.99 | -0.83 | +16.2% | 14.28 | -3.1% | -3.5% | +8.1% | -4.7% | -3.2% | -7.9% | — |
| Nov 6, 2025 | AMC | -1.02 | -0.92 | +9.8% | 12.32 | -25.7% | -22.7% | -21.0% | -17.4% | -23.0% | -29.6% | — |
| Aug 7, 2025 | AMC | -1.03 | -0.99 | +3.9% | 11.46 | +0.4% | -5.8% | -6.3% | -5.2% | -4.0% | -4.9% | — |
| May 8, 2025 | AMC | -1.26 | -1.10 | +12.7% | 8.28 | +1.7% | -1.9% | +3.3% | +0.5% | -4.8% | -2.5% | — |
| Feb 27, 2025 | AMC | -1.32 | -1.24 | +6.1% | 10.86 | -5.4% | -7.1% | -13.0% | -16.2% | -13.7% | -8.8% | — |
| Nov 7, 2024 | AMC | -1.37 | -1.34 | +2.2% | 16.00 | +0.3% | +4.6% | +9.4% | +4.1% | +0.7% | -5.5% | — |
| Aug 8, 2024 | AMC | -1.21 | -1.31 | -8.3% | 22.38 | +0.1% | -4.1% | -2.7% | +0.1% | -3.9% | +2.2% | — |
| May 9, 2024 | AMC | -1.35 | -1.06 | +21.5% | 24.86 | +0.6% | -1.6% | +2.3% | +3.5% | +5.5% | +5.3% | — |
| Feb 22, 2024 | AMC | -1.47 | -1.46 | +0.7% | 27.18 | -1.7% | -4.0% | +1.8% | +14.1% | +20.7% | +18.2% | — |
| Nov 9, 2023 | AMC | -1.52 | -1.38 | +9.2% | 24.96 | +0.4% | -3.3% | -4.6% | +6.0% | +6.5% | +4.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Citizens | Maintains | Market Outperform → Market Outperform | — | $13.04 | $12.82 | -1.7% | +1.2% | -4.5% | +3.4% | +1.7% | — |
| Apr 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.04 | $12.82 | -1.7% | +1.2% | -4.5% | +3.4% | +1.7% | — |
| Apr 28 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.04 | $12.82 | -1.7% | +1.2% | -4.5% | +3.4% | +1.7% | — |
| Apr 28 | Goldman Sachs | Maintains | Sell → Sell | — | $13.04 | $12.82 | -1.7% | +1.2% | -4.5% | +3.4% | +1.7% | — |
| Apr 27 | Baird | Maintains | Neutral → Neutral | — | $13.63 | $14.23 | +4.4% | -4.3% | -3.2% | -8.7% | -1.1% | -2.7% |
| Apr 27 | Chardan Capital | Maintains | Buy → Buy | — | $13.63 | $14.23 | +4.4% | -4.3% | -3.2% | -8.7% | -1.1% | -2.7% |
| Mar 4 | Jones Trading | Upgrade | Hold → Buy | — | $13.61 | $13.98 | +2.7% | +1.5% | -3.4% | -1.2% | +2.1% | -1.0% |
| Mar 3 | Leerink Partners | Maintains | Outperform → Outperform | — | $15.44 | $14.79 | -4.2% | -11.9% | -10.5% | -14.8% | -13.0% | -10.0% |
| Mar 3 | Citizens | Maintains | Market Outperform → Market Outperform | — | $15.44 | $14.79 | -4.2% | -11.9% | -10.5% | -14.8% | -13.0% | -10.0% |
| Mar 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $15.44 | $14.79 | -4.2% | -11.9% | -10.5% | -14.8% | -13.0% | -10.0% |
Recent Filings
8-K
Intellia Therapeutics, Inc. -- 8-K Filing
Intellia Therapeutics completed an underwritten public offering under its shelf registration, with standard indemnification provisions protecting underwriters from securities law liabilities.
Apr 30
8-K · 7.01
! Medium
Intellia Therapeutics, Inc -- 8-K 7.01: Regulation FD Disclosure
Intellia Therapeutics disclosed material information via press release and presentation, requiring investors to review the furnished exhibits for details on company developments or announcements.
Apr 27
8-K
Unknown — 8-K Filing
Intellia Therapeutics updated its corporate bylaws, likely reflecting governance changes that could affect shareholder voting rights, board structure, or operational procedures—investors should review specifics for potential impacts on corporate control.
Apr 10
8-K · 7.01
! Medium
Intellia Therapeutics, Inc -- 8-K 7.01: Regulation FD Disclosure
Intellia Therapeutics (NTLA) can resume its MAGNITUDE Phase 3 clinical trial for ATTR-CM treatment after the FDA lifted a clinical hold, potentially accelerating the company's path toward commercialization.
Mar 2
8-K
Intellia Therapeutics, Inc -- 8-K Filing
Intellia Therapeutics expects to submit a lonvo-z BLA for hereditary angioedema in late 2026 with anticipated U.S. launch in early 2027, while reactivating its MAGNITUDE-2 trial for nex-z in ATTR amyloidosis.
Feb 26
Data updated apr 26, 2026 3:59pm
· Source: massive.com